ArticlePloS one2011
siRNA-like double-stranded RNAs are specifically protected against degradation in human cell extract.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Mathematical model for the role of multiple pericentromeric repeats on heterochromatin assembly.PLoS computational biology · 2024Article
- Analyzing siRNA Concentration, Complexation and Stability in Cationic Dendriplexes by Stem-Loop Reverse Transcription-qPCR.Pharmaceutics · 2022Article
- Are We Studying Non-Coding RNAs Correctly? Lessons from nc886.International journal of molecular sciences · 2022Review
- Co-delivery of Bmi1 small interfering RNA with ursolic acid by folate receptor-targeted cationic liposomes enhances anti-tumor activity of ursolic acidDrug delivery · 2019Article
- Chronic dysfunction of Stromal interaction molecule by pulsed RNAi induction in fat tissue impairs organismal energy homeostasis in Drosophila.Scientific reports · 2019Article
- Mapping the sugar dependency for rational generation of a DNA-RNA hybrid-guided Cas9 endonuclease.Nature communications · 2017Article
- Versatile RNA tetra-U helix linking motif as a toolkit for nucleic acid nanotechnology.Nanomedicine : nanotechnology, biology, and medicine · 2017Article
- Live cell imaging of duplex siRNA intracellular trafficking.Nucleic acids research · 2015Article
- Engineered RNA Nanodesigns for Applications in RNA Nanotechnology.DNA and RNA nanotechnology · 2015Article
- RNA/aTNA chimeras: RNAi effects and nucleases resistance of single and double stranded RNAs.Molecules (Basel, Switzerland) · 2014Article
- In silico design and enzymatic synthesis of functional RNA nanoparticles.Accounts of chemical research · 2014Article
- Deep Sequencing Insights in Therapeutic shRNA Processing and siRNA Target Cleavage Precision.Molecular therapy. Nucleic acids · 2014Article
- Co-transcriptional production of RNA-DNA hybrids for simultaneous release of multiple split functionalities.Nucleic acids research · 2014Article
- Minimal-length Synthetic shRNAs Formulated with Lipid Nanoparticles are Potent Inhibitors of Hepatitis C Virus IRES-linked Gene Expression in Mice.Molecular therapy. Nucleic acids · 2013Article
- Activation of different split functionalities on re-association of RNA-DNA hybrids.Nature nanotechnology · 2013Article
- RNA interference trigger variants: getting the most out of RNA for RNA interference-based therapeutics.Nucleic acid therapeutics · 2012Review
- Subcellular fate and off-target effects of siRNA, shRNA, and miRNA.Pharmaceutical research · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
RNA interference (RNAi) is a set of intracellular pathways in eukaryotes that controls both exogenous and endogenous gene expression. The power of RNAi to knock down (silence) any gene of interest by the introduction of synthetic small-interfering (si)RNAs has afforded powerful insight into biological function through reverse genetic approaches and has borne a new field of gene therapeutics. A number of questions are outstanding concerning the potency of siRNAs, necessitating an understanding of how short double-stranded RNAs are processed by the cell. Recent work suggests unmodified siRNAs are protected in the intracellular environment, although the mechanism of protection still remains unclear. We have developed a set of doubly-fluorophore labeled RNAs (more precisely, RNA/DNA chimeras) to probe in real-time the stability of siRNAs and related molecules by fluorescence resonance energy transfer (FRET). We find that these RNA probes are substrates for relevant cellular degradative processes, including the RNase H1 mediated degradation of an DNA/RNA hybrid and Dicer-mediated cleavage of a 24-nucleotide (per strand) double-stranded RNA. In addition, we find that 21- and 24-nucleotide double-stranded RNAs are relatively protected in human cytosolic cell extract, but less so in blood serum, whereas an 18-nucleotide double-stranded RNA is less protected in both fluids. These results suggest that RNAi effector RNAs are specifically protected in the cellular environment and may provide an explanation for recent results showing that unmodified siRNAs in cells persist intact for extended periods of time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.